Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Remimazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.38 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remimazolam SCHEMBL30237991 | 1.00 | GABRA1 (0.38) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL825168 | 1.00 | GABRA1 (0.38) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL30788432 | 1.00 | GABRA1 (0.38) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL1539505 | 1.00 | GABRA1 (0.38) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL29379706 | 0.96 | GABRA1 (0.37) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL23735014 | 0.93 | GABRA1 (0.42) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL29379415 | 0.93 | GABRA1 (0.42) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL846435 | 0.93 | GABRA1 (0.42) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Remimazolam SCHEMBL29579211 | 0.93 | GABRA1 (0.42) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL25310982 | 0.93 | GABRA1 (0.40) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717696-A1 | METHOD FOR PREPARING REMIMAZOLAM BESYLATE WITH HIGH EFFICIENCY | Hana Pharm. Co. Ltd. (KR) | 2026-04-01 | — | — | EP | claimed |
| US-12331053-B2 | Method for obtaining amorphous remimazolam besylate | MOEHS IBERICA, S.L. (ES) | 2025-06-17 | — | — | US | claimed |
| EP-4556068-A2 | ORALLY INHALED AND NASAL BENZODIAZEPINES | Paion UK Limited (GB) | 2025-05-21 | — | — | EP | claimed |
| EP-3442539-B1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | PAION UK LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| WO-2025038446-A2 | USE OF REMIMAZOLAM FOR PEDIATRIC SEDATION | EAGLE PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2024242468-A1 | METHOD FOR PREPARING REMIMAZOLAM BESYLATE WITH HIGH EFFICIENCY | 하나제약 주식회사 | 2024-11-28 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2023037237-A1 | PROCESS FOR THE PREPARATION OF REMIMAZOLAM | WAVELENGTH ENTERPRISES LTD (IL) | 2023-03-16 | — | — | WO | claimed |
| US-20220402923-A1 | METHOD FOR OBTAINING AMORPHOUS REMIMAZOLAM BESYLATE | MOEHS IBERICA, S.L. (ES) | 2022-12-22 | — | — | US | claimed |
| EP-4003995-A1 | METHOD FOR OBTAINING AMORPHOUS REMIMAZOLAM BESYLATE | Moehs Ibérica, S.L. (ES) | 2022-06-01 | — | — | EP | claimed |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | SEAPORT THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4717696-A1 | METHOD FOR PREPARING REMIMAZOLAM BESYLATE WITH HIGH EFFICIENCY | Hana Pharm. Co. Ltd. (KR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4717696-A1 | METHOD FOR PREPARING REMIMAZOLAM BESYLATE WITH HIGH EFFICIENCY | Hana Pharm. Co. Ltd. (KR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4717696-A1 | METHOD FOR PREPARING REMIMAZOLAM BESYLATE WITH HIGH EFFICIENCY | Hana Pharm. Co. Ltd. (KR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4695257-A1 | PROCESS FOR THE PREPARATION OF REMIMAZOLAM AND SALTS THEREOF | Harman Finochem Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4003995-A1 | METHOD FOR OBTAINING AMORPHOUS REMIMAZOLAM BESYLATE | Moehs Ibérica, S.L. (ES) | 2022-06-01 | — | — | EP | disclosed |
| EP-4003995-A1 | METHOD FOR OBTAINING AMORPHOUS REMIMAZOLAM BESYLATE | Moehs Ibérica, S.L. (ES) | 2022-06-01 | — | — | EP | disclosed |
| US-20220143038-A1 | LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOF | PURETECH LYT, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11304954-B2 | Lipid prodrugs of mycophenolic acid and uses thereof | PURETECH LYT, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | GABRA1 3441/4885GABRA5 2930/4885GABRA3 3462/4885 |
| US-11304954-B2 | Lipid prodrugs of mycophenolic acid and uses thereof | MALT1, CYP2B6, LIPA | GABRA1 3507/4885GABRA5 2643/4885GABRA3 3551/4885 |
| US-12331053-B2 | Method for obtaining amorphous remimazolam besylate | MAP2, MAG, NEFM | GABRA1 102/4885GABRA5 30/4885GABRA3 39/4885 |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | JAK1, JAK3, JAK2 | GABRA1 3433/4885GABRA5 3713/4885GABRA3 3194/4885 |
| US-20220143038-A1 | LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOF | MALT1, CYP2B6, LIPA | GABRA1 3507/4885GABRA5 2643/4885GABRA3 3551/4885 |
| US-20220402923-A1 | METHOD FOR OBTAINING AMORPHOUS REMIMAZOLAM BESYLATE | MAP2, MAG, NEFM | GABRA1 102/4885GABRA5 30/4885GABRA3 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.